Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 10,000 shares of Odonate Therapeutics stock in a transaction on Thursday, November 1st. The stock was acquired at an average cost of $14.87 per share, with a total value of $148,700.00. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Odonate Therapeutics stock opened at $17.21 on Tuesday. Odonate Therapeutics Inc has a one year low of $14.06 and a one year high of $32.00.
Odonate Therapeutics (NASDAQ:ODT) last released its earnings results on Tuesday, October 23rd. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.02). Sell-side analysts anticipate that Odonate Therapeutics Inc will post -3.49 EPS for the current fiscal year.
Separately, Zacks Investment Research raised Odonate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $31.00.
Several large investors have recently added to or reduced their stakes in the company. Birchview Capital LP acquired a new position in shares of Odonate Therapeutics during the 3rd quarter worth $388,000. Alps Advisors Inc. raised its stake in shares of Odonate Therapeutics by 21.9% during the 3rd quarter. Alps Advisors Inc. now owns 47,584 shares of the company’s stock worth $924,000 after buying an additional 8,562 shares during the last quarter. Northern Trust Corp raised its stake in shares of Odonate Therapeutics by 6.0% during the 2nd quarter. Northern Trust Corp now owns 74,510 shares of the company’s stock worth $1,645,000 after buying an additional 4,204 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Odonate Therapeutics by 375.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 81,426 shares of the company’s stock worth $1,799,000 after buying an additional 64,310 shares during the last quarter. Finally, Redmile Group LLC raised its stake in shares of Odonate Therapeutics by 2.8% during the 2nd quarter. Redmile Group LLC now owns 610,600 shares of the company’s stock worth $13,482,000 after buying an additional 16,400 shares during the last quarter. 87.16% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/11/06/odonate-therapeutics-inc-odt-ceo-kevin-c-tang-acquires-10000-shares.html.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Further Reading: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.